In last trading session, Arcutis Biotherapeutics Inc (NASDAQ:ARQT) saw 1.66 million shares changing hands with its beta currently measuring 1.50. Company’s recent per share price level of $13.42 trading at $0.43 or 3.31% at ring of the bell on the day assigns it a market valuation of $1.57B. That closing price of ARQT’s stock is at a discount of -20.72% from its 52-week high price of $16.20 and is indicating a premium of 47.91% from its 52-week low price of $6.99.

For Arcutis Biotherapeutics Inc (ARQT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.22. Splitting up the data highlights that, out of 3 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.26 in the current quarter.

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) trade information

Upright in the green during last session for gaining 3.31%, in the last five days ARQT remained trading in the green while hitting it’s week-highest on Thursday, 02/20/25 when the stock touched $13.42 price level, adding 2.33% to its value on the day. Arcutis Biotherapeutics Inc’s shares saw a change of -3.66% in year-to-date performance and have moved 1.59% in past 5-day. Arcutis Biotherapeutics Inc (NASDAQ:ARQT) showed a performance of 2.60% in past 30-days.

Wall Street analysts have assigned a consensus price target of 19 to the stock, which implies a rise of 29.37% to its current value. Analysts have been projecting 19 as a low price target for the stock while placing it at a high target of 19. It follows that stock’s current price would drop -41.58% in reaching the projected high whereas dropping to the targeted low would mean a loss of -41.58% for stock’s current value.

Arcutis Biotherapeutics Inc (ARQT) estimates and forecasts

This year revenue growth is estimated to rise 211.19% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 60.52M for the same. And 4 analysts are in estimates of company making revenue of 63.19M in the next quarter. Company posted 13.53M and 49.57M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -48.07% during past 5 years.

Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s Major holders

JENNISON ASSOCIATES LLC is the top institutional holder at ARQT for having 11.57 million shares of worth $107.62 million. And as of 2024-06-30, it was holding 9.3712 of the company’s outstanding shares.

The second largest institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, which was holding about 10.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.1021 of outstanding shares, having a total worth of $93.04 million.

On the other hand, Vanguard Total Stock Market Index Fund and PGIM Jennison Small Company Fd are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 3.59 shares of worth $48.17 million or 3.07% of the total outstanding shares. The later fund manager was in possession of 3.09 shares on Nov 30, 2024 , making its stake of worth around $41.4 million in the company or a holder of 2.64% of company’s stock.